Advances and challenges in pathomics for liver cancer: From diagnosis to prognostic stratification.

IF 2.6 Q3 ONCOLOGY
Ming-Hui Peng, Kai-Lun Zhang, Shi-Wei Guan, Quan Lin, Hai-Bo Yu
{"title":"Advances and challenges in pathomics for liver cancer: From diagnosis to prognostic stratification.","authors":"Ming-Hui Peng, Kai-Lun Zhang, Shi-Wei Guan, Quan Lin, Hai-Bo Yu","doi":"10.5306/wjco.v16.i6.107646","DOIUrl":null,"url":null,"abstract":"<p><p>Hepatocellular carcinoma (HCC), a leading cause of cancer mortality, faces diagnostic and therapeutic challenges due to its histopathological complexity and clinical heterogeneity. Pathomics, an emerging discipline that integrates artificial intelligence (AI) with quantitative pathology image analysis, aims to decode disease heterogeneity by extracting high-dimensional features from histopathological specimens. This review highlights how AI-driven pathomics has revolutionized liver cancer management through automated analysis of whole-slide images. Pathomics integrates deep learning with histopathological features to enable precise tumour classification (<i>e.g.</i>, HCC <i>vs</i> cholangiocarcinoma), microvascular invasion (MVI) detection, recurrence risk stratification, and survival prediction. Advanced frameworks such as MVI-AI diagnostic model and CHOWDER demonstrate high accuracy in identifying prognostic biomarkers, whereas multiomics integration links morphometric patterns to molecular signatures (<i>e.g.</i>, <i>EZH2</i> expression and immune infiltration). Despite these breakthroughs, critical bottlenecks persist, including limited multicentre validation studies, \"black box\" model interpretability, and clinical workflow integration. Future studies should emphasize AI-enhanced multimodal fusion (radiogenomics and liquid biopsy) and standardized platforms to bridge computational pathology and precision oncology, ultimately improving personalized therapeutic strategies for liver malignancies. This synthesis aims to guide research translation and advance personalized therapeutic strategies for liver malignancies.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 6","pages":"107646"},"PeriodicalIF":2.6000,"publicationDate":"2025-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12198871/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"World journal of clinical oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5306/wjco.v16.i6.107646","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Hepatocellular carcinoma (HCC), a leading cause of cancer mortality, faces diagnostic and therapeutic challenges due to its histopathological complexity and clinical heterogeneity. Pathomics, an emerging discipline that integrates artificial intelligence (AI) with quantitative pathology image analysis, aims to decode disease heterogeneity by extracting high-dimensional features from histopathological specimens. This review highlights how AI-driven pathomics has revolutionized liver cancer management through automated analysis of whole-slide images. Pathomics integrates deep learning with histopathological features to enable precise tumour classification (e.g., HCC vs cholangiocarcinoma), microvascular invasion (MVI) detection, recurrence risk stratification, and survival prediction. Advanced frameworks such as MVI-AI diagnostic model and CHOWDER demonstrate high accuracy in identifying prognostic biomarkers, whereas multiomics integration links morphometric patterns to molecular signatures (e.g., EZH2 expression and immune infiltration). Despite these breakthroughs, critical bottlenecks persist, including limited multicentre validation studies, "black box" model interpretability, and clinical workflow integration. Future studies should emphasize AI-enhanced multimodal fusion (radiogenomics and liquid biopsy) and standardized platforms to bridge computational pathology and precision oncology, ultimately improving personalized therapeutic strategies for liver malignancies. This synthesis aims to guide research translation and advance personalized therapeutic strategies for liver malignancies.

肝癌病理的进展与挑战:从诊断到预后分层。
肝细胞癌(HCC)是癌症死亡的主要原因之一,由于其组织病理学的复杂性和临床异质性,面临着诊断和治疗方面的挑战。病理学是一门将人工智能(AI)与定量病理图像分析相结合的新兴学科,旨在通过从组织病理标本中提取高维特征来解码疾病异质性。这篇综述强调了人工智能驱动的病理学如何通过对整个幻灯片图像的自动分析彻底改变了肝癌的管理。病理学将深度学习与组织病理学特征相结合,以实现精确的肿瘤分类(例如,HCC与胆管癌)、微血管侵袭(MVI)检测、复发风险分层和生存预测。先进的框架,如mi - ai诊断模型和CHOWDER,在识别预后生物标志物方面具有很高的准确性,而多组学整合将形态计量学模式与分子特征(例如,EZH2表达和免疫浸润)联系起来。尽管取得了这些突破,但关键的瓶颈仍然存在,包括有限的多中心验证研究、“黑盒”模型可解释性和临床工作流程集成。未来的研究应强调人工智能增强的多模式融合(放射基因组学和液体活检)和标准化平台,以架起计算病理学和精确肿瘤学的桥梁,最终改善肝脏恶性肿瘤的个性化治疗策略。这一综合旨在指导研究转化和推进肝脏恶性肿瘤的个性化治疗策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
585
期刊介绍: The WJCO is a high-quality, peer reviewed, open-access journal. The primary task of WJCO is to rapidly publish high-quality original articles, reviews, editorials, and case reports in the field of oncology. In order to promote productive academic communication, the peer review process for the WJCO is transparent; to this end, all published manuscripts are accompanied by the anonymized reviewers’ comments as well as the authors’ responses. The primary aims of the WJCO are to improve diagnostic, therapeutic and preventive modalities and the skills of clinicians and to guide clinical practice in oncology. Scope: Art of Oncology, Biology of Neoplasia, Breast Cancer, Cancer Prevention and Control, Cancer-Related Complications, Diagnosis in Oncology, Gastrointestinal Cancer, Genetic Testing For Cancer, Gynecologic Cancer, Head and Neck Cancer, Hematologic Malignancy, Lung Cancer, Melanoma, Molecular Oncology, Neurooncology, Palliative and Supportive Care, Pediatric Oncology, Surgical Oncology, Translational Oncology, and Urologic Oncology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信